close
close

Omeros Corporation Announces Upcoming Presentations at the European Hematology Association (EHA) Hybrid Congress 2024

— Interim Analysis Data from Ongoing Phase 2 Study of WHO906 in Paroxysmal Nocturnal Hemoglobinuria Selected for Podium Presentation —

SEATTLE, May 9, 2024–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER) today announced that interim analytical data from its ongoing Phase 2 study of OMS906 in patients with paroxysmal nocturnal hemoglobinuria submitted to the Hybrid Congress 2024 from the European Hematology Association (EHA) were selected. for a podium presentation. The EHA Congress will be held June 13-16, 2024 in Madrid, Spain. OMS906 is Omeros’ investigational MASP-3 inhibitor targeting the alternative complement pathway. Two additional poster presentations for OMS906 will also be presented at the conference.

Abstracts of the three presentations are expected to be released on May 14, 2024 and will be available on the EHA website at ehaweb.org. Details of the conference presentations can be found below.

OMS906, a novel alternative pathway MASP-3 inhibitor, improved hematologic parameters in PNH patients with suboptimal response to ravilizumab treatment: interim results from the phase 2 dose-finding study (abstract n ° S189)
Session name: s454 Clinical and translational in bone marrow failure syndromes and PNH
Date: Saturday June 15, 2024
Podium presentation session time: 4:30 p.m. CEST
Location: IFEMA Madrid Recinto Ferial (Fair), Hall N102
Presenting author: Morag Griffin MBChB, FRCPath

Clinical Pharmacology of WHO906, a Potent Inhibitor of MASP-3 and the Alternative Pathway of Complement Activation (Abstract No. P834)
Date: Friday June 14, 2024
Presentation time: 6:00 p.m. – 7:00 p.m. CEST
Location: IFEMA Madrid Recinto Ferial (Fair), Hall 7
Presenting author: William Pullman MB BS, PhD, FRACP

Exposure-response modeling using population PK/PD methods reliably predicts population and individual responses of mature complement factor D, hemoglobin, and LDH in PNH patients exposed to WHO906 (Abstract No. P1920)
Date: Friday June 14, 2024
Location: IFEMA Madrid Recinto Ferial (Fair), Hall 7
Presenting author: William Pullman MB BS, PhD, FRACP

Presentation materials associated with each abstract will be available on the Omeros website at www.omeros.com following the conference presentations.

About WHO906

OMS906 is an investigational humanized monoclonal antibody targeting mannan-binding lectin-associated serine protease-3 (MASP-3), the key activator of the alternative pathway of the complement system. The complement system plays a central role in inflammation and is activated following tissue damage or microbial infection. Responsible for the conversion of pro-complement factor D to complementary factor D, MASP-3 is considered the main target of the alternative pathway – it has the lowest native circulating level and low relative clearance compared to other proteins of the alternative pathway and, unlike C5 and C3 blockers, inhibition of MASP-3 leaves intact the lytic arm of the classical pathway, important for fighting infection. Furthermore, unlike other components of the alternative pathway, MASP-3 is not thought to be an acute phase reactant, which could confer a significant advantage to MASP-3 inhibitors, such as OMS906, by compared to other inhibitors of the alternative pathway. MASP-3 inhibitors are thought to have preventive and/or therapeutic effects on a wide range of diseases, including paroxysmal nocturnal hemoglobinuria (PNH), hemolytic uremic syndrome (HUS), atypical HUS, traumatic brain injury. , arthritis, wet age-related macular degeneration. , ischemia-reperfusion injury, transplantation-related complications, and other immune-related disorders.

About Omeros

Omeros is an innovative biopharmaceutical company engaged in the discovery, development and commercialization of small molecule and protein-based therapeutics for large-market and orphan indications targeting immunological disorders, including complement-mediated diseases, cancers and addictive and compulsive disorders. Narsoplimab, Omeros’ lead MASP-2 inhibitor, targets the complement lectin pathway and is the subject of a pending Biologics License Application with the FDA for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplantation. Omeros’ long-acting MASP-2 inhibitor, OMS1029, is currently in a multiple-ascending-dose Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the key activator of the alternative complement pathway, is advancing toward Phase 3 clinical trials for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Funded by the Institute National Drug Abuse Control Agency, Omeros’ lead phosphodiesterase 7 inhibitor, OMS527, is in clinical development for the treatment of cocaine use disorders and, in addition, is being developed as a therapeutic for other addictions as well as for a major complication of treatment. for movement disorders. Omeros is also developing a broad portfolio of novel immuno-oncology programs including two cellular and three molecular platforms. For more information about Omeros and its programs, visit www.omeros.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240509156472/en/

Contacts

Jennifer Cook-Williams
Cook Williams Communications, Inc.
Investor and media relations
[email protected]